在前列腺癌治疗中,用非编码RNA重写雄激素向治疗的耐药性
Chamikara Liyanage1, Judith Clements2, Jyotsna Batra3
1School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, QLD 4059, Australia; Cancer Program, The Centre for Genomics and Personalised Health and ARC Training Centre for Cell and Tissue Engineering Technologies (CTET), Queensland University of Technology, Brisbane, QLD 4059, Australia; Translational Research Institute, Queensland University of Technology, Woolloongabba, QLD 4102, Australia.
非编码RNAs (ncRNAs) 是前列腺癌的关键调节者,驱动对雄激素向治疗的耐药性. 了解ncRNA机制为生物标志物和晚期前列腺癌的治疗提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 前列腺癌是男性的主要癌症,经常对标准的雄激素向治疗产生抵抗力.
- 转移性割抵抗性前列腺癌 (mCRPC) 是由适应性抵抗机制引起的.
- 曾经被忽视的非编码RNA (ncRNA) 现在被认为是关键的基因调节器.
研究的目的:
- 审查ncRNA介导的分子机制,驱动前列腺癌中对雄激素向治疗的耐药性.
- 探索ncRNAs作为前列腺癌进展的生物标志物的潜力.
- 讨论ncRNAs作为克服治疗耐药性的治疗点.
主要方法:
- 对前列腺癌中ncRNAs研究的文献综述.
- 通过ncRNAs调节的分子通路在治疗耐药性的分析.
- 对ncRNA临床应用的当前研究的综合.
主要成果:
- ncRNAs在前列腺癌的发展和进展中起着至关重要的作用.
- ncRNAs可以重新连接致癌和瘤抑制器信号通路,从而导致治疗抵抗.
- 特定的ncRNAs涉及到过渡到抵抗割的前列腺癌.
结论:
- 在前列腺癌中,ncRNA是不可或缺的调节剂,特别是在治疗耐药性的背景下.
- ncRNAs作为诊断生物标志物和晚期前列腺癌的治疗点具有显著的前景.
- 针对ncRNAs可能提供新的策略来规避耐药性并改善患者的治疗结果.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
08:36Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses
Published on: October 24, 2019
相关概念视频
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
MicroRNAs
Targeted Cancer Therapies
There are several types of targeted therapies against...
lncRNA - Long Non-coding RNAs
Treatment Resistant Cancers
